HAIFA, Israel, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has selected Fisher BioServices, Inc. as worldwide dispatch distributor of its off-the-shelf PLacental eXpanded (PLX) cells. Fisher BioServices will provide cryogenic storage and distribution of Pluristem's PLX cells for its clinical trials and preclinical sites around the world. Pluristem currently is targeting several therapeutics indications for which clinical trials and preclinical studies are in progress, which include: a) intermittent claudication; b) muscle regeneration c) critical limb ischemia d) Buerger's disease; and e) acute radiation syndrome. The different studies are scheduled to take place in Europe, India, Israel and the U.S. In addition, Pluristem has reported strong pre-clinical study results in other indications for which the company may pursue clinical trials in the future. These include the treatment of acute myocardial infarction (heart attack), lung disease, and bone marrow disease. These indications collectively represent multibillion dollar treatment markets. Fisher BioServices is the world's leading provider of specialized biological sample and material management, and cell therapy logistics services to pharmaceutical and biotech companies, and national, state and academic institutions. Equipped to provide storage and cold chain transportation capabilities for the entire spectrum of cell-based and regenerative medicine worldwide, Fisher BioServices also provides distribution of cell-based therapies from manufacturer to patient bedside, with complete chain of custody documentation. "As we expand our roster of clinical trials for our PLX cell therapies for several indications, we needed a reliable leader in cell therapy distribution. Fisher BioServices was the clear choice for us because they are the world's leader in biological materials handling and have supported hundreds of clinical trials," said Zami Aberman, Chairman and CEO of Pluristem. About Pluristem Therapeutics Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem is focusing on the development of PLX cells administered locally to potentially treat systemic diseases and potentially obviating the need to use the intravenous route.